METHODS	In this randomized , open-label trial , 871 patients with advanced HCC throughout China were treated with 10 % UBC three times per day plus best supportive care ( BSC ; n = 439 ) or BSC alone excluding all creams ( n = 432 ) , starting on day 1 of sorafenib treatment , for up to 12 weeks .\